Tower Research Capital LLC TRC increased its stake in shares of Celgene Co. (NASDAQ:CELG) by 44,330.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,886 shares of the biopharmaceutical company’s stock after acquiring an additional 8,866 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Celgene were worth $1,154,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Thompson Davis & CO. Inc. boosted its stake in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares in the last quarter. Motco boosted its stake in Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares in the last quarter. Penserra Capital Management LLC bought a new position in Celgene during the second quarter worth $129,000. Acropolis Investment Management LLC bought a new position in Celgene during the second quarter worth $144,000. Finally, Rational Advisors LLC bought a new position in Celgene during the second quarter worth $156,000. 80.17% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have weighed in on the stock. Atlantic Securities upgraded shares of Celgene from a “neutral” rating to an “overweight” rating in a report on Friday. Cann restated a “buy” rating and set a $166.00 price objective on shares of Celgene in a report on Wednesday, November 22nd. TheStreet downgraded shares of Celgene from a “b-” rating to a “c+” rating in a report on Friday, November 17th. BMO Capital Markets upped their price objective on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, November 17th. Finally, Canaccord Genuity set a $140.00 price objective on shares of Celgene and gave the stock a “buy” rating in a report on Thursday, November 16th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $139.57.
Celgene Co. (NASDAQ CELG) opened at $106.09 on Monday. The firm has a market cap of $83,530.00, a PE ratio of 16.58, a P/E/G ratio of 0.82 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.58 earnings per share. equities analysts forecast that Celgene Co. will post 6.67 EPS for the current year.
In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Celgene Co. (CELG) Shares Bought by Tower Research Capital LLC TRC” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/celgene-co-celg-shares-bought-by-tower-research-capital-llc-trc.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.